The first participants in Moderna’s clinical trial have been vaccinated against Bundibugyo Ebola virus as the company begins Phase 1 trials in Canada.
The vaccine is being developed using Moderna's mRNA platform, the same underlying technology used in its COVID-19 vaccine, the company said in a press release.